Clinical trial
A Multi-centre Randomized, Placebo-controlled Trial of Mirabegron, a New beta3-adrenergic Receptor Agonist on Left Ventricular Mass and Diastolic Function in Patients With Structural Heart Disease
NCT02599480 is registered in ClinicalTrials.gov with Jean-Luc Balligand as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Multi-centre Randomized, Placebo-controlled Trial of Mirabegron, a New beta3-adrenergic Receptor Agonist on Left Ventricular Mass and Diastolic Function in Patients With Structural Heart Disease
- Lead sponsor
- Jean-Luc Balligand
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- September 12, 2016
- Completion date
- February 16, 2022
- Enrollment
- 296 (actual)
- Sites
- 10
Conditions
As the registry lists them; a condition with its own page is linked.